Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report

RATIONALE: Pembrolizumab, an immune-checkpoint inhibitor (ICI), has been shown to be effective for treatment-naive patients with non–small cell lung cancer (NSCLC) and high expression of programmed death-ligand 1 (PD-L1). Therefore, treatment regimens containing pembrolizumab have become a standard...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Medicine (Baltimore)
Asıl Yazarlar: Yamasaki, Masahiro, Funaishi, Kunihiko, Kawamoto, Kazuma, Matsumoto, Yu, Matsumoto, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki, Hattori, Noboru
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wolters Kluwer Health 2019
Konular:
5700
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6831270/
https://ncbi.nlm.nih.gov/pubmed/31415404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000016834
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller